All studies
Ongoing, recruitingHuman Pharmacology (Phase I)- OtherInterventional
Phase 1 study of NG-641 plus nivolumab (or standard of care PD-1) in metastatic or advanced epithelial tumours (NEBULA)
At a glance
Status
Ongoing, recruiting
Phase
Human Pharmacology (Phase I)- Other
Sponsor
Akamis Bio Limited
Enrolment target
85
Start
23 May 2023
Who may be eligible?
Age 18 Years to any · Sex: All
Locations (2)
- —Belgium
- —Spain
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.